The Development of SARS-CoV-2 Nucleocapsid Specific Monoclonal Antibodies

A recent Science Direct publication highlights the development of generating SARS-CoV-2 nucleocapsid specific monoclonal antibodies to help supply new tools to specifically target SARS-CoV-2, the causative agent resulting in COVID-19. The study refers to nucleocapsid proteins, mBG86 and mBG17 antibody expression plasmids, available to purchase on our catalog, here. The plasmids are originally provided from 

Continue Reading…

How RNase HI Inhibition Could be the Key to Combatting Multi-Drug Resistant Tuberculosis

The development of antibiotics and therapeutics have been instrumental in the economic development that the world experiences today. Lifesaving therapeutics are threatened by the increasing prevalence of multi-drug resistant strains of bacteria, one of which includes Mycobacterium tuberculosis (MDR-TB). The first-line antibiotic treatments for tuberculosis are rifampicin and isoniazid. MDR-TB has shown resistance to these 

Continue Reading…